Anti-cancer drug profiling and biomarker identification
OncoPanel™ services provide multi-parametric drug response data across a panel of 300 genomically diverse cancer cell lines that span 19 different cancer tissues. Therapeutics may be tested in the entire panel or a subset that contains any combination of the 300 available cancer cell lines. Using high content imaging, simultaneous detection of anti-cancer activity and detection of pharmacodynamic biomarkers in a single, multiplexed assay may be provided.
OncoPanel™ services allow a detailed understanding of drug response that cannot be achieved by single endpoint assay profiling. Assay endpoints can be customized to measure up to four biological pathways or processes at once (cell viability, apoptosis, mitotic block and custom markers). Genomic analysis of OncoPanel™ data enables the discovery of predictive biomarkers to help determine which genomic features may predispose patients to therapeutic response.
Cell surface expression of your target antigen can be measured in live cells to correlate antigen expression with therapeutic response in the same assay. OncoPanel™ can also provide quantitative binding analysis of therapeutic antibodies within the same multiplexed assay.
Study design to match your project goals
As assays become more sophisticated, it is often necessary to tailor parameters to the specific question that is being asked. Our experience working with a variety of different molecules, such as kinase inhibitors, epigenetic modulators and large molecule biologics, ensures that we can generate the best study design for your project.
|Figure 1. OncoPanel™ service work flow||Figure 2. OncoPanel™ services powered by quality and interpretation drives|
Lab automation and non-contact liquid dispensing (left), along with strict cell culture procedure, drives the consistency behind OncoPanel™ service. The true power of OncoPanel™ lies in the ability to decipher predictive biomarkers (right) to support clinical trials later in development.